Publications

Found 1 results
Filters: Author is N. Vairavan  [Clear All Filters]
2012
K. A. Muthusamy, Lian, L. H., Vairavan, N., Chua, K. H., and Waran, V., Genetic polymorphisms of EGF 5'-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients, vol. 11, pp. 2939-2945, 2012.
Agundez JA, Jimenez-Jimenez FJ, Luengo A, Molina JA, et al. (1998). Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 51: 1587-1592. http://dx.doi.org/10.1212/WNL.51.6.1587 PMid:9855506   Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, et al. (1996). Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276: 1494-1501. http://dx.doi.org/10.1001/jama.1996.03540180050032 PMid:8903261   Bhowmick DA, Zhuang Z, Wait SD and Weil RJ (2004). A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 64: 1220-1223. http://dx.doi.org/10.1158/0008-5472.CAN-03-3137 PMid:14973082   Butcher NJ, Boukouvala S, Sim E and Minchin RF (2002). Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2: 30-42. http://dx.doi.org/10.1038/sj.tpj.6500053 PMid:11990379   Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, et al. (1995). Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57: 581-592. PMid:7668286 PMCid:1801274   Chua KH, Kee BP, Tan SY and Lian LH (2009a). Interleukin-6 promoter polymorphisms (-174 G/C) in Malaysian patients with systemic lupus erythematosus. Braz. J. Med. Biol. Res. 42: 551-555. http://dx.doi.org/10.1590/S0100-879X2009000600012 PMid:19448905   Chua KH, Lau TP, Tee ZY, Tan SY, et al. (2009b). Genetic polymorphisms of the IL-1 511 and +3954 SNPs in the Malaysian SLE patients. J. Health Sci. 55: 657-662. http://dx.doi.org/10.1248/jhs.55.657   Chua KH, Lian LH, Kee BP, Thum CM, et al. (2011a). Identification of DLG5 and SLC22A5 gene polymorphisms in Malaysian patients with Crohn's disease. J. Dig. Dis. 12: 459-466. http://dx.doi.org/10.1111/j.1751-2980.2011.00533.x PMid:22118696   Chua KH, Puah SM, Chew CH, Wong CH, et al. (2011b). Interaction between a novel intronic IVS3+172 variant and N29I mutation in PRSS1 gene is associated with pancreatitis in a Malaysian Chinese family. Pancreatology 11: 441-444. http://dx.doi.org/10.1159/000330943 PMid:21952138   Costa BM, Ferreira P, Costa S, Canedo P, et al. (2007). Association between functional EGF+61 polymorphism and glioma risk. Clin. Cancer Res. 13: 2621-2626. http://dx.doi.org/10.1158/1078-0432.CCR-06-2606 PMid:17473192   Davis FG, Freels S, Grutsch J, Barlas S, et al. (1998). Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88: 1-10. http://dx.doi.org/10.3171/jns.1998.88.1.0001 PMid:9420066   Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, et al. (2006). Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev. 32: 74-89. http://dx.doi.org/10.1016/j.ctrv.2006.01.003 PMid:16488082   Kleihues P and Cavanee WK (2000). Pathology and Genetics of Tumours of the Nervous System. 2nd edn. IARC Press, Lyon.   Liu Y, Shete S, Hosking FJ, Robertson LB, et al. (2010). New insights into susceptibility to glioma. Arch. Neurol. 67: 275-278. http://dx.doi.org/10.1001/archneurol.2010.4 PMid:20212223   Ng ZX, Kuppusamy UR, Tajunisah I, Fong KC, et al. (2012). 2245G/A polymorphism of the receptor for advanced glycation end-products (RAGE) gene is associated with diabetic retinopathy in the Malaysian population. Br. J. Ophthalmol. 96: 289-292. http://dx.doi.org/10.1136/bjophthalmol-2011-300658 PMid:22116960 PMCid:3261748   Nicholson RI, Gee JM and Harper ME (2001). EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl 4): S9-15. http://dx.doi.org/10.1016/S0959-8049(01)00231-3   Olayioye MA, Neve RM, Lane HA and Hynes NE (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19: 3159-3167. http://dx.doi.org/10.1093/emboj/19.13.3159 PMid:10880430 PMCid:313958   Salomon DS, Brandt R, Ciardiello F and Normanno N (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19: 183-232. http://dx.doi.org/10.1016/1040-8428(94)00144-I   Shahbazi M, Pravica V, Nasreen N, Fakhoury H, et al. (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401. http://dx.doi.org/10.1016/S0140-6736(02)07600-6   Thong KL, Lai MY, Teh CS and Chua KH (2011). Simultaneous detection of methicillin-resistant Staphylococcus aureus, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa by multiplex PCR. Trop. Biomed. 28: 21-31. PMid:21602765   von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, et al. (1999). Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv. Exp. Med. Biol. 455: 147-152. http://dx.doi.org/10.1007/978-1-4615-4857-7_21 PMid:10599336